Akzo Nobel to Open Coil Coatings Facility at its Suzhou, China Site
May 23, 2002 04:19 ET
|
Akzo Nobel
ARNHEM, The Netherlands, May 23, 2002 (PRIMEZONE) -- Rudy van der Meer, member of Akzo Nobel's Board of Management responsible for Coatings, today announced that Akzo Nobel is in the process of...
Pharmexa Plans Clinical Trials in the U.S.A and Releases New Data from Its AutoVac HER-2 Protein Breast Cancer Product
May 21, 2002 06:41 ET
|
Pharmexa A/S
HARSHOLM, Denmark, May 21, 2002 (PRIMEZONE) -- Following a successful pre-IND meeting with the Food and Drug Administration (FDA) in the United States, Pharmexa has decided to conduct the first...
American Physicians Service Group, Inc. Reports First Quarter Earnings
May 16, 2002 09:29 ET
|
American Physicians Service Group, Inc.
AUSTIN, Texas, May 16, 2002 (PRIMEZONE) -- American Physicians Service Group, Inc. ("APS") (Nasdaq:AMPH) today announced results for the first quarter of 2002. For the three months ended March 31,...
Claus Braestrup is Proposed as New Chairman of the Board of Directors in Pharmexa
May 16, 2002 05:10 ET
|
Pharmexa A/S
HORSHOLM, Denmark, May 16, 2002 (PRIMEZONE) -- The Board of Directors in Pharmexa propose that Executive Vice President of Research and Development in H. Lundbeck, Claus Braestrup is elected new...
Pharmexa In-Licenses Formulation Technology from ZYCOS for the AutoVac HER-2 DNA Therapeutic Cancer Vaccine
May 15, 2002 08:26 ET
|
Pharmexa A/S
HORSHOLM, Denmark, May 15, 2002 (PRIMEZONE) -- Pharmexa and ZYCOS today jointly announced that they have entered into an agreement to formulate Pharmexa's therapeutic DNA breast cancer vaccine in...
CeNeS Announces Further Progress in Its Neuropathic Pain Phase II Programme
May 15, 2002 02:31 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., May 15, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced postive interim results from Phase II trials of CNS 5161 for neuropathic pain.
Results from a single...
atugen Announces Functional Genomics Collaboration with Byk Gulden
May 14, 2002 02:44 ET
|
atugen AG
BERLIN, Germany, May 14, 2002 (PRIMEZONE) -- atugen AG today announced a three year, collaboration with Byk Gulden, the pharmaceutical group of ALTANA AG, to validate a number of novel genetic...
CeNeS Pre-clinical Candidate rhGGF2 Cited as Potential Treatment for Schizophrenia
May 14, 2002 02:37 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., May 14, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today noted recent press coverage on the identification of a risk gene for schizophrenia that has implications for its...
Astex Announces Appointment of Vice President of Biology
May 14, 2002 02:30 ET
|
Astex Therapeutics
CAMBRIDGE, U.K., May 14, 2002 (PRIMEZONE) -- Astex Technology, the structure-based drug discovery company pioneering the use of high throughput X-ray crystallography technology, today announced the...
Artimplant Interim Report, January 1- March 31, 2002
May 03, 2002 03:46 ET
|
Artimplant
STOCKHOLM, Sweden, May 3, 2002 (PRIMEZONE) -- Artimplant:
-- Confidential negotiations on licenses and partnership agreements are
under way with several global enterprises in the field of...